|
|
| Year : 1996 | Volume
: 17
| Issue : 4 | Page : 196-199 |
|
|
Comparative evaluation of ondansetron vs metoclopromide/dexamethasone combination as antiemetic in cisplatin based cancer chemotherapy.
A Biswas, R Tandon, A Chakrabarti, SK Bhattacharya
Dept of Pharmocology, Institute of Medical Sciences, B.H.U. Varanasi, India
Correspondence Address:
A Biswas
Dept of Pharmocology, Institute of Medical Sciences, B.H.U. Varanasi, India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Platinum based chemotherapy induced nausea and vomiting are major side effects and often significant cause of noncompliance in cancer therapy. The present study was performed to assess the potential of a newer antiemetic agent ondansetron against the conventional combination of metoclopramide and dexamethasone. Twenty two patients receiving cisplatinum (75mg/m2)on D1 were evaluated. Twelve patients received metoclopramide(1.5mg/kg)plus dexamethasone(16mg)every twelve hourly, while ten patients received ondansetron(8mg)every 12hourly on first day. The mean time of onset of nausea was significantly delayed in ondansetron group(10.33+/-1.52)hrs vs 4.61+/-0.99hrs,P0.001)the mean number of emetic episodes was also less in ondansetron treated group (0.44+/-0.22vs2.08+/-0.49,P,0.01). Complete control of emesis was achieved in 70 in odansetron group compared to 25 in metoclopramide dexamethasone group. We conclude that ondansetron is superior to metoclopramide and dexamethasone combination in control of cisplatinum induced nausea and vomiting. |
|
|
|
| [PDF Not available]* |
|
 |
|
